tRNA

Cancer cells with mutated p53 undergo apoptosis by stalling ribosomes at rare leucine codons, inhibiting protein translation.

By engineering cells to translate quadruplet codons instead of the standard triplets, scientists expand the possible amino acids that can be integrated into proteins, paving the way for novel protein-based therapeutics and research tools.

aTyr Pharma initiates two new tRNA synthetase discovery programs